Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

A Northumberland woman whose husband was diagnosed with a rare form of cancer has joined leading charities to call on the Health Secretary to review a decision to block a "lifeline" treatment. Dr ...

The University of Iowa Health Care Holden Comprehensive Cancer Center has started treating its second patient — the second in the state — with a cellular therapy to fight synovial sarcoma, a rare and ...

T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...

A new study has revealed a promising new approach to curb the spread of triple-negative breast cancer, one of the most aggressive and difficult-to-treat forms of the disease. Published recently in ...

NEW YORK – Ohio State University researchers are using urine samples to understand bladder cancer patients' tumor microenvironments in several ongoing clinical trials, and they're confident the method ...

As a world leader in the immuno-oncology field, Dr. Zihai Li has long been at the forefront of cancer immunotherapy.

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

Cancer immunotherapy has transformed oncology, yet many patients fail to respond or eventually develop resistance.

A group of natural compounds attracting attention for their anti-aging potential has a dark side. New research shows how a ...

A naturally occurring byproduct of liver metabolism–the ketone body, β-hydroxybutyrate (BHB)–can strengthen the fitness and antitumor activity of CAR T cells.